This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 237 results found since Jan 2013.
CardioPulse Articles * Gerhard Hindricks MD * Cardiac Centres Of Excellence * Leipzig Heart Centre - Department of Electrophysiology * New perspectives for stroke prevention in atrial fibrillation * Syncope and near drowning may signal sudden death risk * Ear stimulation for atrial fibrillation favoured at ESC Congress London
Source: European Heart Journal - February 14, 2016 Category: Cardiology Tags: CardioPulse Source Type: research
Coronary microcirculatory pathophysiology: can we afford it to remain a black box?
<span class="paragraphSection"><div class="boxTitle">Abstract</div>Coronary microvascular networks play the key role in determining blood flow distribution in the heart. Matching local blood supply to tissue metabolic demand entails continuous adaptation of coronary vessels via regulation of smooth muscle tone and structural dilated vessel diameter. The importance of coronary microcirculation for relevant pathological conditions including angina in patients with normal or near-normal coronary angiograms [microvascular angina (MVA)] and heart failure with preserved ejection fraction (HFpEF) is increasingly...
Source: European Heart Journal - February 2, 2016 Category: Cardiology Source Type: research
Heart failure: when form fails to follow function
Cardiac performance is normally determined by architectural, cellular, and molecular structures that determine the heart's form, and by physiological and biochemical mechanisms that regulate the function of these structures. Impaired adaptation of form to function in failing hearts contributes to two syndromes initially called systolic heart failure (SHF) and diastolic heart failure (DHF). In SHF, characterized by high end-diastolic volume (EDV), the left ventricle (LV) cannot eject a normal stroke volume (SV); in DHF, with normal or low EDV, the LV cannot accept a normal venous return. These syndromes are now generally de...
Source: European Heart Journal - February 1, 2016 Category: Cardiology Authors: Katz, A. M., Rolett, E. L. Tags: Clinical update Source Type: research
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial
Conclusions Extended DAPT did not achieve superiority in reducing net adverse clinical events compared to 12 months of DAPT after DES placement. The power of the OPTIDUAL trial was however low and reduced by premature termination of enrolment. ClinicalTrials.gov number NCT00822536.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Helft, G., Steg, P. G., Le Feuvre, C., Georges, J.-L., Carrie, D., Dreyfus, X., Furber, A., Leclercq, F., Eltchaninoff, H., Falquier, J.-F., Henry, P., Cattan, S., Sebagh, L., Michel, P.-L., Tuambilangana, A., Hammoudi, N., Boccara, F., Cayla, G., Douard, Tags: ESC Hot Line Source Type: research
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
Conclusion Compared with aspirin alone, DAPT beyond 1 year among stabilized high-risk patients with prior MI decreases ischaemic events, including significant reductions in the individual endpoints of cardiovascular death, recurrent MI, and stroke. Dual antiplatelet therapy beyond 1 year increases major bleeding, but not fatal bleeding or non-cardiovascular death.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Udell, J. A., Bonaca, M. P., Collet, J.-P., Lincoff, A. M., Kereiakes, D. J., Costa, F., Lee, C. W., Mauri, L., Valgimigli, M., Park, S.-J., Montalescot, G., Sabatine, M. S., Braunwald, E., Bhatt, D. L. Tags: Coronary artery disease Source Type: research
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Conclusion In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Magnani, G., Storey, R. F., Steg, G., Bhatt, D. L., Cohen, M., Kuder, J., Im, K., Aylward, P., Ardissino, D., Isaza, D., Parkhomenko, A., Goudev, A. R., Dellborg, M., Kontny, F., Corbalan, R., Medina, F., Jensen, E. C., Held, P., Braunwald, E., Sabatine, Tags: Thrombosis and antithrombotic therapy Source Type: research
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
Conclusions Neoplasm events were infrequent during long-term DAPT after ACS, were associated with differential cancer-screening practices across regions, and the frequency of neoplasm detection was similar with prasugrel vs. clopidogrel. Trial registration ClinicalTrials.gov identifier: NCT00699998.
Source: European Heart Journal - January 21, 2016 Category: Cardiology Authors: Roe, M. T., Cyr, D. D., Eckart, D., Schulte, P. J., Morse, M. A., Blackwell, K. L., Ready, N. E., Zafar, S. Y., Beaven, A. W., Strickler, J. H., Onken, J. E., Winters, K. J., Houterloot, L., Zamoryakhin, D., Wiviott, S. D., White, H. D., Prabhakaran, D., Tags: Acute coronary syndromes Source Type: research
Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study
Conclusion Among patients undergoing non-cardiac surgery, pre-operative statin therapy was independently associated with a lower risk of cardiovascular outcomes at 30 days. These results require confirmation in a large randomized trial. Clinical trial registration Clinical Trials.gov NCT00512109
Source: European Heart Journal - January 7, 2016 Category: Cardiology Authors: Berwanger, O., Le Manach, Y., Suzumura, E. A., Biccard, B., Srinathan, S. K., Szczeklik, W., Santo, J. A. E., Santucci, E., Cavalcanti, A. B., Archbold, R. A., Devereaux, P. J., for the VISION Investigators Tags: ESC Clinical Registry Source Type: research
Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts
Conclusion In patients with stable ischaemic heart disease, higher GDF11/8 levels are associated with lower risk of cardiovascular events and death. Our findings suggest that GDF11/8 has similar cardioprotective properties in humans to those demonstrated in mice.
Source: European Heart Journal - December 21, 2015 Category: Cardiology Authors: Olson, K. A., Beatty, A. L., Heidecker, B., Regan, M. C., Brody, E. N., Foreman, T., Kato, S., Mehler, R. E., Singer, B. S., Hveem, K., Dalen, H., Sterling, D. G., Lawn, R. M., Schiller, N. B., Williams, S. A., Whooley, M. A., Ganz, P. Tags: Pathophysiology Source Type: research
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial
Conclusion In the ARISTOTLE trial, women had a similar rate of stroke or systemic embolism but a lower risk of mortality and less clinically relevant bleeding than men. The efficacy and safety benefits of apixaban compared with warfarin were consistent in men and women. Trial registration ARISTOTLE ClinicalTrials.gov number, NCT00412984.
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: Vinereanu, D., Stevens, S. R., Alexander, J. H., Al-Khatib, S. M., Avezum, A., Bahit, M. C., Granger, C. B., Lopes, R. D., Halvorsen, S., Hanna, M., Husted, S., Hylek, E. M., Mărgulescu, A. D., Wallentin, L., Atar, D. Tags: Atrial fibrillation Source Type: research
Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study
Conclusion Both in the overall population as well as in the angina subset, bradycardia was common in ivabradine-treated patients, but did not appear to impact outcomes. Emergent AF was relatively rare and did not appear to have an impact on outcomes relative to placebo. Clinical trials registration ISRCTN61576291
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., Ferrari, R., the SIGNIFY investigators Tags: Coronary artery disease Source Type: research
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
Conclusions The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support clinical decision making.
Source: European Heart Journal - December 7, 2015 Category: Cardiology Authors: O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., Pencina, M. J., Piccini, J. P., Peterson, E. D. Tags: Atrial fibrillation Source Type: research
CardioPulse Articles * The 2015 ESC Guidelines on the diagnosis and management of pericardial diseases * 'Ten Commandments' of 2015 ESC Guidelines for diagnosis and management of pericardial diseases * The Russian National Congress of Cardiology 2015 * Germany's largest heart centre * Professor Christoph Bode * Professor Franz-Josef Neumann * The CHA2DS2-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief history
Source: European Heart Journal - November 7, 2015 Category: Cardiology Tags: CardioPulse Source Type: research
Cardiovascular disease in Europe -- epidemiological update 2015
This article provides an update for 2015 on the burden of cardiovascular disease (CVD), with a particular focus on coronary heart disease (CHD) and stroke, across the countries of Europe. Cardiovascular disease is still the most common cause of death within Europe, causing almost two times as many deaths as cancer across the continent. Although there is clear evidence, where data are available, that mortality from CHD and stroke has decreased substantially over the last 5–10 years, there are still large inequalities found between European countries, in both current rates of death and the rate at which these decreases...
Source: European Heart Journal - October 21, 2015 Category: Cardiology Authors: Townsend, N., Nichols, M., Scarborough, P., Rayner, M. Tags: Prevention and epidemiology Source Type: research
Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men
Conclusion In this large observational cohort with extended follow-up, normalization of TT levels after TRT was associated with a significant reduction in all-cause mortality, MI, and stroke.
Source: European Heart Journal - October 21, 2015 Category: Cardiology Authors: Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., Sharma, R., Parashara, D., Savin, V. J., Ambrose, J. A., Barua, R. S. Tags: Coronary artery disease Source Type: research
Calcification of the mitral valve complicated by embolization and subsequent ischemic stroke with haemorrhagic transformation
Source: European Heart Journal - October 21, 2015 Category: Cardiology Authors: Denegri, A., Pedrazzini, G. B., Moccetti, T., Moccetti, M. Tags: CARDIOVASCULAR FLASHLIGHTS Source Type: research
Road traffic noise is associated with increased cardiovascular morbidity and mortality and all-cause mortality in London
Conclusions Long-term exposure to road traffic noise was associated with small increased risks of all-cause mortality and cardiovascular mortality and morbidity in the general population, particularly for stroke in the elderly.
Source: European Heart Journal - October 14, 2015 Category: Cardiology Authors: Halonen, J. I., Hansell, A. L., Gulliver, J., Morley, D., Blangiardo, M., Fecht, D., Toledano, M. B., Beevers, S. D., Anderson, H. R., Kelly, F. J., Tonne, C. Tags: Prevention and epidemiology Source Type: research
Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
Conclusion The majority of deaths occurred in patients who did not experience a non-fatal CV or renal event, although the risk of death was higher following an event. Our findings illustrate continuing opportunities to reduce morbidity and mortality in patients with type 2 diabetes.
Source: European Heart Journal - September 21, 2015 Category: Cardiology Authors: Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., Pfeffer, M. A. Tags: Prevention and epidemiology Source Type: research
Ischaemic stroke and ST-segment elevation myocardial infarction: fast-track single-stop approach
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Lanzer, P., Widimsky, P. Tags: CURRENT OPINION Source Type: research
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research
Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial
Conclusions The blinded placebo-controlled STOP-HF trial demonstrated the safety of a single endocardial administration of pSDF-1 but failed to demonstrate its primary endpoint of improved composite score at 4 months after treatment. Through a pre-specified analysis the STOP-HF trial demonstrates the potential for attenuating LV remodelling and improving EF in high-risk ischaemic cardiomyopathy. The safety profile supports repeat dosing with pSDF-1 and the degree of left ventricular remodelling suggests the potential for improved outcomes in larger future trials.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Chung, E. S., Miller, L., Patel, A. N., Anderson, R. D., Mendelsohn, F. O., Traverse, J., Silver, K. H., Shin, J., Ewald, G., Farr, M. J., Anwaruddin, S., Plat, F., Fisher, S. J., AuWerter, A. T., Pastore, J. M., Aras, R., Penn, M. S. Tags: Heart failure/cardiomyopathy Source Type: research
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial
Conclusions Patients randomized to the LDE treated with amiodarone at the time of randomization demonstrated a significant reduction in ischaemic events vs. warfarin when compared with those not on amiodarone, while preserving a favourable bleeding profile. In contrast, amiodarone had no effect on the relative efficacy and safety of HDE.
Source: European Heart Journal - September 1, 2015 Category: Cardiology Authors: Steffel, J., Giugliano, R. P., Braunwald, E., Murphy, S. A., Atar, D., Heidbuchel, H., Camm, A. J., Antman, E. M., Ruff, C. T. Tags: Thrombosis and anti-thrombotic therapy Source Type: research
A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial
Conclusion TriGuard cerebral protection during TAVI is safe and complete cerebral vessel coverage was achieved in 89% of subjects. In this exploratory study, subjects undergoing protected TAVI had more freedom from ischaemic brain lesions, fewer neurologic deficits, and improved cognitive function in some domains at discharge and 30 days compared with controls.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Lansky, A. J., Schofer, J., Tchetche, D., Stella, P., Pietras, C. G., Parise, H., Abrams, K., Forrest, J. K., Cleman, M., Reinohl, J., Cuisset, T., Blackman, D., Bolotin, G., Spitzer, S., Kappert, U., Gilard, M., Modine, T., Hildick-Smith, D., Haude, M., Tags: FASTTRACK EuroPCR Source Type: research
Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion of Doppler and computed tomographic data
Conclusion The fusion AVAi reclassifies 52% of normal flow–low gradient and 12% of low flow–low gradient severe AS into true moderate AS, by providing true cross-sectional LVOT area.
Source: European Heart Journal - August 14, 2015 Category: Cardiology Authors: Kamperidis, V., van Rosendael, P. J., Katsanos, S., van der Kley, F., Regeer, M., Al Amri, I., Sianos, G., Marsan, N. A., Delgado, V., Bax, J. J. Tags: Valvular heart disease Source Type: research
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Conclusions LCZ696 was superior to enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure, which accounted for the majority of cardiovascular deaths. Clinical Trial Registration https://clinicaltrials.gov/, NCT01035255.
Source: European Heart Journal - August 7, 2015 Category: Cardiology Authors: Desai, A. S., McMurray, J. J. V., Packer, M., Swedberg, K., Rouleau, J. L., Chen, F., Gong, J., Rizkala, A. R., Brahimi, A., Claggett, B., Finn, P. V., Hartley, L. H., Liu, J., Lefkowitz, M., Shi, V., Zile, M. R., Solomon, S. D. Tags: Heart failure/cardiomyopathy Source Type: research
CardioPulse Articles * Editors' network of the European Society of Cardiology National Cardiovascular Journals: scientific input from the National Societies * Hand grip strength predicts myocardial infarction and stroke * Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Source: European Heart Journal - August 3, 2015 Category: Cardiology Tags: CardioPulse Source Type: research
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Conclusion In patients with ACS, ticagrelor pharmacokinetics is influenced by three genetic loci (SLCO1B1, UGT2B7, and CYP3A4). However, the modest genetic effects on ticagrelor plasma levels did not translate into any detectable effect on efficacy or safety during ticagrelor treatment. Clinical trial registration NCT00391872
Source: European Heart Journal - August 3, 2015 Category: Cardiology Authors: Varenhorst, C., Eriksson, N., Johansson, A., Barratt, B. J., Hagstrom, E., Akerblom, A., Syvanen, A.-C., Becker, R. C., James, S. K., Katus, H. A., Husted, S., Steg, P. G., Siegbahn, A., Voora, D., Teng, R., Storey, R. F., Wallentin, L., on behalf of the Tags: Acute coronary syndromes Source Type: research
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation
Conclusion In patients undergoing CA for AF, the use of uninterrupted oral rivaroxaban was feasible and event rates were similar to those for uninterrupted VKA therapy. Name of the Trial Registry Clinicaltrials.gov trial registration number is NCT01729871.
Source: European Heart Journal - July 21, 2015 Category: Cardiology Authors: Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., Vijgen, J., Hugl, B. J., Balasubramaniam, R., De Chillou, C., Davies, D. W., Fields, L. E., Natale, A., on behalf Tags: Atrial fibrillation Source Type: research
Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project
Conclusion In patients with non-valvular AF, left-sided valvular heart disease (excluding mitral stenosis and protheses) was associated with an increased risk of stroke/TE events. A higher CHA2DS2VASc score in these patients is likely to explain these results.
Source: European Heart Journal - July 21, 2015 Category: Cardiology Authors: Philippart, R., Brunet-Bernard, A., Clementy, N., Bourguignon, T., Mirza, A., Babuty, D., Angoulvant, D., Lip, G. Y. H., Fauchier, L. Tags: CLINICAL RESEARCH Source Type: research
Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)
Conclusion Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure. Study registration number NCT00644410 (ClinicalTrials.gov).
Source: European Heart Journal - July 14, 2015 Category: Cardiology Authors: Mathiasen, A. B., Qayyum, A. A., Jorgensen, E., Helqvist, S., Fischer-Nielsen, A., Kofoed, K. F., Haack-Sorensen, M., Ekblond, A., Kastrup, J. Tags: Interventional cardiology Source Type: research
Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices
Conclusion In patients with implanted defibrillators, the strategy of early initiation and interruption of anticoagulation based on remotely detected AT did not prevent thromboembolism and bleeding. Clinical trial registration IMPACT ClinicalTrials.gov identifier: NCT00559988 http://clinicaltrials.gov/ct2/show/NCT00559988?term=NCT00559988&rank=1.
Source: European Heart Journal - July 7, 2015 Category: Cardiology Authors: Martin, D. T., Bersohn, M. M., Waldo, A. L., Wathen, M. S., Choucair, W. K., Lip, G. Y. H., Ip, J., Holcomb, R., Akar, J. G., Halperin, J. L., on behalf of the IMPACT Investigators Tags: Atrial fibrillation Source Type: research
Novel risk markers and mediators in coronary disease and stroke
Source: European Heart Journal - July 1, 2015 Category: Cardiology Authors: Luscher, T. F. Tags: ISSUE @ A GLANCE Source Type: research
Stroke: a rare but devastating procedural complication of PCI
Source: European Heart Journal - July 1, 2015 Category: Cardiology Authors: James, S. Tags: EDITORIALS Source Type: research
Shooting vascular oxidative stress: new hopes for stroke patients?
Source: European Heart Journal - July 1, 2015 Category: Cardiology Authors: Volpe, M., Paneni, F. Tags: EDITORIALS Source Type: research
Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies
Conclusion Orthostatic hypotension is associated with a significantly increased risk of all-cause death, incident CHD, HF, and stroke.
Source: European Heart Journal - July 1, 2015 Category: Cardiology Authors: Ricci, F., Fedorowski, A., Radico, F., Romanello, M., Tatasciore, A., Di Nicola, M., Zimarino, M., De Caterina, R. Tags: Hypertension Source Type: research
Late intracardiac orthopedic wire migration presenting as tamponade and stroke
Source: European Heart Journal - June 21, 2015 Category: Cardiology Authors: Hedon, C., Khoueiry, Z., Verges, M., Pasquie, J.-L. Tags: CARDIOVASCULAR FLASHLIGHTS Source Type: research
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation
Conclusion In patients with AF, edoxaban appeared to demonstrate greater efficacy compared with warfarin in patients who were VKA naive than VKA experienced. Edoxaban significantly reduced major bleeding compared with warfarin regardless of prior VKA exposure.
Source: European Heart Journal - June 14, 2015 Category: Cardiology Authors: O'Donoghue, M. L., Ruff, C. T., Giugliano, R. P., Murphy, S. A., Grip, L. T., Mercuri, M. F., Rutman, H., Shi, M., Kania, G., Cermak, O., Braunwald, E., Antman, E. M. Tags: Atrial fibrillation Source Type: research
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting
Conclusions In the present trial, characterized by low event rates, we did not observe a significant difference in net clinical outcome between 6 and 12 months of clopidogrel therapy after DES implantation. However, the results of the trial must be considered in view of its premature termination and lower than expected event rates. The trial is registered with ClinicalTrials.gov, Identifier: NCT00661206.
Source: European Heart Journal - May 21, 2015 Category: Cardiology Authors: Schulz-Schupke, S., Byrne, R. A., ten Berg, J. M., Neumann, F.-J., Han, Y., Adriaenssens, T., Tolg, R., Seyfarth, M., Maeng, M., Zrenner, B., Jacobshagen, C., Mudra, H., von Hodenberg, E., Wohrle, J., Angiolillo, D. J., von Merzljak, B., Rifatov, N., Kufn Tags: Thrombosis and antithrombotic therapy Source Type: research
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial
Conclusion Major bleeding was associated with substantially increased risk of death, ischaemic stroke, or MI, especially following ICH, and this risk was similarly elevated regardless of treatment with apixaban or warfarin. These results underscore the importance of preventing bleeding in anti-coagulated patients. Clinical Trials.gov identifier NCT00412984.
Source: European Heart Journal - May 21, 2015 Category: Cardiology Authors: Held, C., Hylek, E. M., Alexander, J. H., Hanna, M., Lopes, R. D., Wojdyla, D. M., Thomas, L., Al-Khalidi, H., Alings, M., Xavier, D., Ansell, J., Goto, S., Ruzyllo, W., Rosenqvist, M., Verheugt, F. W. A., Zhu, J., Granger, C. B., Wallentin, L. Tags: Thrombosis and antithrombotic therapy Source Type: research
Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
Conclusions Risk of cardiovascular events appeared high beyond the first year post-MI, indicating a need for prolonged surveillance, particularly in patients with additional risk factors.
Source: European Heart Journal - May 14, 2015 Category: Cardiology Authors: Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., Janzon, M. Tags: Acute coronary syndrome Source Type: research
Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study)
Conclusion Rheumatic heart disease patients were young, predominantly female, and had high prevalence of major cardiovascular complications. There is suboptimal utilization of secondary antibiotic prophylaxis, oral anti-coagulation, and contraception, and variations in the use of percutaneous and surgical interventions by country income level.
Source: European Heart Journal - May 7, 2015 Category: Cardiology Authors: Zuhlke, L., Engel, M. E., Karthikeyan, G., Rangarajan, S., Mackie, P., Cupido, B., Mauff, K., Islam, S., Joachim, A., Daniels, R., Francis, V., Ogendo, S., Gitura, B., Mondo, C., Okello, E., Lwabi, P., Al-Kebsi, M. M., Hugo-Hamman, C., Sheta, S. S., Haile Tags: Valvular heart disease Source Type: research
Silent myocardial infarction and stroke: findings of multimodality imaging
Source: European Heart Journal - April 21, 2015 Category: Cardiology Authors: Taniwaki, M., Windecker, S., Raber, L. Tags: CARDIOVASCULAR FLASHLIGHTS Source Type: research
Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study
Conclusion We found an increased risk of myocardial infarction in the period following the initiation of antipsychotics that was not attributable to differences between people prescribed and not prescribed antipsychotics.
Source: European Heart Journal - April 21, 2015 Category: Cardiology Authors: Brauer, R., Smeeth, L., Anaya-Izquierdo, K., Timmis, A., Denaxas, S. C., Farrington, C. P., Whitaker, H., Hemingway, H., Douglas, I. Tags: Acute coronary syndromes Source Type: research
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
This study is registered at clinicaltrials.gov-NCT00417222.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Sakata, Y., Shiba, N., Takahashi, J., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., Nakagawa, M., Sekiguchi, N., Komaru, T., Kato, A., Fukuchi, M., Nozaki, E., Hiramoto, T., Inoue, K., Goto, T., Ohe, M., Tamaki, K., I Tags: Heart failure/cardiomyopathy Source Type: research
Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence
Conclusion Regardless of recent advances in PAD treatment, current outcomes remain poor especially in CLI. Despite overwhelming evidence for reduction of limb loss by revascularization, CLI patients still received significantly less angiographies and revascularizations.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Reinecke, H., Unrath, M., Freisinger, E., Bunzemeier, H., Meyborg, M., Luders, F., Gebauer, K., Roeder, N., Berger, K., Malyar, N. M. Tags: Peripheral artery disease Source Type: research
CardioPulse Articles * Andreas Gruntzig's beginnings started in peripheral arteries * Developments in the treatment of aortic aneurysms in 2014 * Interventional treatment of venous thromboembolism * From academia to industry * Working in industry requires wanting to make medicines * STEMI and stroke: distant cousins at best
Source: European Heart Journal - March 7, 2015 Category: Cardiology Tags: CardioPulse Source Type: research
Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study
Conclusion For type 2 diabetes, the MHO phenotype is associated with lower risk than the metabolically unhealthy obese, but for CVD the risk is as elevated in both obesity phenotypes.
Source: European Heart Journal - March 1, 2015 Category: Cardiology Authors: Hinnouho, G.-M., Czernichow, S., Dugravot, A., Nabi, H., Brunner, E. J., Kivimaki, M., Singh-Manoux, A. Tags: Prevention and epidemiology Source Type: research
Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes
Conclusion Differences in baseline characteristics in patients with increasing severities of PVR may increase the risk of this complication. Despite these differences, multivariable analysis demonstrated that both mild and moderate/severe PVR predicted higher 1-year mortality.
Source: European Heart Journal - February 14, 2015 Category: Cardiology Authors: Kodali, S., Pibarot, P., Douglas, P. S., Williams, M., Xu, K., Thourani, V., Rihal, C. S., Zajarias, A., Doshi, D., Davidson, M., Tuzcu, E. M., Stewart, W., Weissman, N. J., Svensson, L., Greason, K., Maniar, H., Mack, M., Anwaruddin, S., Leon, M. B., Hah Tags: Valvular heart disease Source Type: research
Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician
Source: European Heart Journal - February 2, 2015 Category: Cardiology Authors: Arkin, J. M., Kowey, P. R. Tags: EDITORIALS Source Type: research